CL2011002569A1 - Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r. - Google Patents

Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.

Info

Publication number
CL2011002569A1
CL2011002569A1 CL2011002569A CL2011002569A CL2011002569A1 CL 2011002569 A1 CL2011002569 A1 CL 2011002569A1 CL 2011002569 A CL2011002569 A CL 2011002569A CL 2011002569 A CL2011002569 A CL 2011002569A CL 2011002569 A1 CL2011002569 A1 CL 2011002569A1
Authority
CL
Chile
Prior art keywords
inhibitor
igf
administering
treatment
tyrosine kinase
Prior art date
Application number
CL2011002569A
Other languages
English (en)
Inventor
Sriram Sathyanarayanan
Shailaja Winter Christopher Chastain Michael Kasibhatla
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2011002569A1 publication Critical patent/CL2011002569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procedimiento de tratamiento o prevención que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
CL2011002569A 2009-04-16 2011-10-14 Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r. CL2011002569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16976809P 2009-04-16 2009-04-16

Publications (1)

Publication Number Publication Date
CL2011002569A1 true CL2011002569A1 (es) 2012-04-09

Family

ID=42982796

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002569A CL2011002569A1 (es) 2009-04-16 2011-10-14 Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.

Country Status (18)

Country Link
US (1) US20120058112A1 (es)
EP (1) EP2419135A4 (es)
JP (1) JP2012524087A (es)
KR (1) KR20110140126A (es)
CN (1) CN102458466A (es)
AU (1) AU2010236818B2 (es)
BR (1) BRPI1015216A2 (es)
CA (1) CA2757730A1 (es)
CL (1) CL2011002569A1 (es)
CO (1) CO6571849A2 (es)
EC (1) ECSP11011405A (es)
IL (1) IL215363A0 (es)
MX (1) MX2011010911A (es)
NZ (1) NZ595755A (es)
RU (1) RU2011146339A (es)
SG (1) SG175208A1 (es)
WO (1) WO2010120592A1 (es)
ZA (1) ZA201107204B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029178B1 (ru) 2008-12-12 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
US8470297B1 (en) * 2009-09-10 2013-06-25 Merck Sharp & Dohme Corp. FDG-pet evaluation of Ewing's sarcoma sensitivity
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
GB201409488D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CN105963305B (zh) * 2016-07-05 2018-08-17 福州大学 一种含酪氨酸激酶抑制剂的药物组合物及其在制备抗肿瘤转移药物中的应用
CN105998033B (zh) * 2016-07-05 2018-11-27 福州大学 一种含有厄洛替尼和熊果酸的药物组合物及其在制备抗肿瘤药物中的应用
EP4426360A1 (en) * 2021-11-02 2024-09-11 Fusion Pharmaceuticals Inc. Methods of treating cancer
WO2023235822A1 (en) * 2022-06-03 2023-12-07 Foundation Medicine, Inc. Igf1r activation mutations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608777A2 (pt) * 2005-04-15 2010-01-26 Schering Corp métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
EP2236139A1 (en) * 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor

Also Published As

Publication number Publication date
RU2011146339A (ru) 2013-05-27
CO6571849A2 (es) 2012-11-30
EP2419135A1 (en) 2012-02-22
ECSP11011405A (es) 2011-11-30
CA2757730A1 (en) 2010-10-21
US20120058112A1 (en) 2012-03-08
ZA201107204B (en) 2015-07-29
SG175208A1 (en) 2011-11-28
MX2011010911A (es) 2011-11-02
IL215363A0 (en) 2011-12-29
JP2012524087A (ja) 2012-10-11
AU2010236818A1 (en) 2011-11-03
BRPI1015216A2 (pt) 2016-04-12
KR20110140126A (ko) 2011-12-30
NZ595755A (en) 2013-07-26
WO2010120592A1 (en) 2010-10-21
EP2419135A4 (en) 2012-11-28
AU2010236818B2 (en) 2014-03-13
CN102458466A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
PH12017500930A1 (en) Hsp90 inhibitor combinations
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
MX346379B (es) Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.
UY31897A1 (es) Combinación de metotrexato con inhibidores dhodh
IN2012DN01869A (es)
IN2012DN03012A (es)
CR20120173A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX355728B (es) Inhibidores de cinasas.
BRPI0912582A2 (pt) Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb
CL2008000290A1 (es) Metodo para tratar un tumor que comprende un antagonista vegf y un inhibidor de proteina quinasa.
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
TR201900319T4 (tr) C1 esteraz inhibitör eksikliği ile ilişkili bozuklukların önlenmesinde ve tedavisinde kullanım için c1-inh bileşimleri ve yöntemler.
DK2358710T3 (da) AKT- og P70-S6-kinaseinhibitorer
GT201400223A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
IN2014DN08385A (es)
IT1393307B1 (it) Dispositivo e procedimento per localizzare scariche parziali.
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
MX2013015357A (es) Terapia de combinacion.
BRPI0921888A2 (pt) terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
DOP2012000253A (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de hiv-1, y un potenciador farmacocinético